Novo Nordisk C-Suite lands in China: What's their big plan?
By CGTN
Community Score: 50% | 179 views | 2w
0 community ratings: null thumbs up, null thumbs down
The Danish pharma giant, the developer of Semaglutide - Novo Nordisk's top executives kicked off a high-stakes visit in China. From speeding up new drug launches for diabetes and weight management, to boosting local investment and joint innovation projects, every stop points to deeper integration into China's fast-growing healthcare sector. As more multinational firms double down on China's market and innovation ecosystem, Novo Nordisk's journey reveals the huge opportunities within the country's “Healthy China” development blueprint. Watch CGTN's full report to unpack all key takeaways. 📺 Subscribe to our YouTube channel and stay updated with our latest analysis and interviews:👇 https://www.youtube.com/channel/UCgrNz-aDmcr2uuto8_DL2jg 👈 Download our APP on Apple Store (iOS): https://itunes.apple.com/us/app/cctvnews-app/id922456579?l=zh&ls=1&mt=8 Download our APP on Google Play (Android): https://play.google.com/store/apps/details?id=com.imib.cctv For more: https://www.cgtn.com
Tags: CGTN, News, China, China news, Breaking news, Current news, Chinese news, CGTN NEWS, CGTN Live, Live CGTN
More from CGTN
- Jeffrey Sachs: US and Israel underestimated Iran — Score: 50%
- Key outcomes of the China-US economic, trade talks in Paris — Score: 50%
- Israeli Prime Minister posts video to prove he is alive #worldnow — Score: 50%
- China's Kuaizhou-11 Y7 rocket launches eight new satellites #coolchina — Score: 50%
- Trump says he 'demands' 7 countries escort ships through Strait of Hormuz #worldnow — Score: 50%
- Live ship tracking map showing the Strait of Hormuz — Score: 50%